Characterization of HKI-272 Covalent Binding to Human Serum Albumin-Reference-Cited by-同舟云学术

Characterization of HKI-272 Covalent Binding to Human Serum Albumin

Published:2010-04-16 Issue:7 Volume:38 Page:1083-1093
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Wang Jianyao,Li-Chan Xiao Xian,Atherton Jim,Deng Lin,Espina Robert,Yu Linning,Horwatt Peter,Ross Steven,Lockhead Susan,Ahmad Syed,Chandrasekaran Appavu,Oganesian Aram,Scatina JoAnn,Mutlib Abdul,Talaat Rasmy

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference25 articles.

1. Peptide Mapping Identifies Hotspot Site of Modification in Human Serum Albumin by Methylglyoxal Involved in Ligand Binding and Esterase Activity

2. Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo

3. Formation of Mono- and Bis-Michael Adducts by the Reaction of Nucleophilic Amino Acids with Hydroxymethylvinyl Ketone, a Reactive Metabolite of 1,3-Butadiene

4. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance;Bertucci;Curr Med Chem,2002

5. Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Localization of Sites of Osimertinib Action in Rat Intestine, Skin, and Lung by Immunohistochemistry;ACTA HISTOCHEMICA ET CYTOCHEMICA;2023-12-28

2. Biotransformation research advances – 2022 year in review;Drug Metabolism Reviews;2023-10-02

3. Metabolism, pharmacokinetics and excretion of [¹⁴C]dimethyl fumarate in healthy volunteers: an example of xenobiotic biotransformation following endogenous metabolic pathways;Xenobiotica;2023-03-04

4. Species differences in plasma protein binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir;Xenobiotica;2023-01-02

5. Drug development of covalent inhibitors;Overcoming Obstacles in Drug Discovery and Development;2023